NCT03947970View on ClinicalTrials.gov

Study to Evaluate the Pharmacokinetics and Metabolism of [14C] CR845 (Difelikefalin) in Patients With End Stage Renal Disease on Hemodialysis and in Healthy Subjects

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

January 17, 2019

Primary Completion Date

April 6, 2019

Study Completion Date

April 6, 2019

Conditions

HemodialysisHealthy

Interventions

DRUG

[14C] CR845

Subjects will receive a single dose of 230 mcg CR845 solution containing 100 microcuries \[14C\] CR845, administered via IV bolus (the total dose of CR845 will range from 1.7 to 3.1 mcg/kg)

Trial Locations (1)

78217

Cara Therapeutics Study Site, San Antonio